Loading stock…

Quest Diagnostics Incorporated (DGX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Quest Diagnostics Incorporated

DGXMarket cap $25BPrice $227.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Runs the largest network of diagnostic testing labs in the U.S., processing over 190 million patient encounters a year. One in three American adults gets tested by Quest at some point in their lives.

In Bastion Portfolios?

52W Return+21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+4%4

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+6%5

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+30%8

EPS Growth Y+2+7%6

EPS Growth Y+3+8%6

Quality

Margins

EBIT Margin15%6

Net Income Margin9%5

Free Cash Flow Margin12%6

Debt

Net Debt/EBITDA2.14

Efficiency

ROE14%6

ROA7%7

Earnings Stability55

GEAR+STRONG71

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)204

P/E Ratio (Forward 3y)174

P/BV3.35

EV Multiples

EV/EBITDA Fwd134

EV/EBIT Fwd165

Yield

Free Cash Flow Yield5.4%7

Dividend Yield1.5%4

Momentum

Short term

1 month return-3%6

3 month return+9%8

YTD return+33%9

Mid term

Price vs 52wHigh92%9

1 year return+28%8

Long term

3 year return+93%7

5 year return+76%7

Risk Shield

Price Risk

Beta0.010

Volatility24%9

Free Cash Flow

Free Cash Flow Margin12%6

Free Cash Flow Yield5.4%7

Quality

ROCE12%6

Earnings Stability55

Net Debt/EBITDA2.14

02Growth

Is it actually growing, and how fast?

DGXQuest Diagnostics

Revenue FY25$11.0B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%4

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+30%8

EPS growth, FY27E+7%6

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+9%8

YTD return+33%9

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+28%8

3-year return+93%7

5-year return+76%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +93% over three years and +76% over five, ahead of 60% of the market.

It's up 28% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+9%) and so far this year (+33%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Quest Diagnostics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DGXQuest Diagnostics

Revenue FY25$11.0B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%4

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+30%8

EPS growth, FY27E+7%6

EPS growth, FY28E+8%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 8%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 6%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG82 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-3%6

3-month return+9%8

YTD return+33%9

MID & LONG-TERM▾SCORE

% of 52-week high92%9

1-year return+28%8

3-year return+93%7

5-year return+76%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +93% over three years and +76% over five, ahead of 60% of the market.

It's up 28% over the past year, but 8% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+9%) and so far this year (+33%).

WATCH

Returns sit at the market level over the past month (-3%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Quest Diagnostics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community